Dyslipidemia Management
Part of concepts/Dyslipidemia — the parent page covers risk assessment, the thresholds for starting therapy, and the treatment goals. This page covers the drugs themselves and the order to use them in.
Definition
Dyslipidemia management is the stepwise pharmacotherapy stack used to get a patient from baseline to an LDL-C goal: a statin first, ezetimibe second, then a PCSK9-directed agent, with bempedoic acid and inclisiran as alternatives when the first three cannot be used. The parent page answers who to treat and how low to go; this page answers with which drug, in what order, and when to stop escalating.
The three guideline frameworks in this wiki agree on the agents and on statin intensity, and disagree on two things: how early to combine agents rather than sequence them, and how to rank everything below PCSK9 inhibition.
Key Concepts
The Escalation Framework
| Step | Class | LDL-C reduction | Position in the pathway |
|---|---|---|---|
| 1 | High-intensity statin | ≥50% | First-line in every risk category with an indication |
| 2 | Ezetimibe | 18% alone; +25% with statin | Add when goal not met on maximum tolerated statin |
| 3 | PCSK9 mAb (evolocumab, alirocumab) | 45–64% | Only after maximum statin plus ezetimibe |
| 3b | Bempedoic acid | 21–24% alone; +17–18% with statin | Statin intolerance; or add-on where PCSK9 mAb unavailable |
| 3c | Inclisiran | 48–52% | Alternative to PCSK9 mAb; twice-yearly dosing |
- Step 1 is not optional where an indication exists. High-intensity statin therapy (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) is COR 1/A in chronic coronary disease, aiming for ≥50% LDL-C reduction; generic formulations are cost-saving and rated high value (sources/CCS-AHA-2023, rating: very high). Post-ACS it is Class I/A, benefit appears early, and therapy should not be de-escalated if tolerated (sources/ACS-AHA-2025, rating: very high).
- Step 2 is ezetimibe, and the sequencing is in the recommendation wording. The PCSK9 mAb recommendation specifies "maximum statin plus ezetimibe" as its precondition, so a PCSK9 inhibitor is not guideline-concordant as the first add-on. The economic argument points the same way: generic ezetimibe is rated high value, PCSK9 mAbs have uncertain economic value at current US prices (sources/CCS-AHA-2023).
- Step 3 carries the strongest outcome evidence below statins. Both PCSK9 mAbs reduced MACE by 15% on top of optimised statin therapy (FOURIER, ODYSSEY OUTCOMES). Trial detail, subgroup data and safety are on concepts/PCSK9-Inhibitors.
- Bempedoic acid and inclisiran are ranked below PCSK9 mAbs at COR 2b in CCS/AHA 2023, reserved for when ezetimibe and a PCSK9 mAb are insufficient or not tolerated. Both rankings are now behind the evidence — CLEAR Outcomes reported a 13% MACE reduction (HR 0.87) after that guideline's literature cutoff. ESC 2025 goes further and makes bempedoic acid COR I B for patients unable to take a statin (sources/lipid-esc-2025, rating: very high).
How early to combine is the live disagreement. CCS/AHA 2023 sequences the agents and reassesses between steps. ESC 2025 recommends initiating high-intensity statin plus ezetimibe together at the index ACS hospitalisation in treatment-naive patients not expected to reach goal on a statin alone (COR IIa B), and intensifying LLT during the index admission for patients already on therapy (COR I C) — a strategy framed as "strike early and strong" (sources/lipid-esc-2025). ACC/AHA's own ACS guideline stops short of that, rating concurrent ezetimibe initiation Class IIb/B-R (sources/ACS-AHA-2025). No trial has compared early combination against sequential escalation on outcomes.
Statin Intensity
| Intensity | LDL-C reduction | Examples |
|---|---|---|
| High | ≥50% | Atorvastatin 40–80 mg; rosuvastatin 20–40 mg |
| Moderate | 30–49% | Atorvastatin 10–20 mg; rosuvastatin 5–10 mg; simvastatin 20–40 mg |
The percentage bands are the ACC/AHA definitions (sources/lipid-aha-2026, rating: very high). Statin-associated diabetes risk is small but real in those with predisposing factors (BMI ≥30, fasting glucose ≥100 mg/dL, metabolic syndrome, HbA1c 6.0–6.4%) and does not justify discontinuation, because the ASCVD benefit is substantially larger (sources/lipid-aha-2026).
Statin-Attributed Muscle Symptoms
- Bilateral, symmetrical proximal myalgia or weakness beginning within weeks of starting, resolving within weeks of stopping. Evaluate secondary causes first (hypothyroidism, vitamin D deficiency, interacting drugs, exertion) before attributing symptoms to the statin.
- The "Drucebo effect" — expectation-driven symptoms, the nocebo counterpart of the placebo response — is common in blinded rechallenge and accounts for a large share of symptoms attributed to statins. There is no objective test that distinguishes true statin intolerance.
- CK measurement only for severe symptoms; routine CK and routine hepatic transaminase monitoring are COR 3: No Benefit during statin therapy (sources/lipid-aha-2026). CoQ10 is likewise COR 3: No Benefit for prevention or treatment of statin muscle symptoms.
- The two clinical rules are COR 1 and they differ by setting. Established ASCVD with SAMS: reduced statin dose plus bempedoic acid, ezetimibe and/or a PCSK9 mAb. High-risk primary prevention with SAMS: bempedoic acid ± ezetimibe, adding a PCSK9 mAb if goals are not met. In both, the guideline directs the clinician to acknowledge the patient's concerns and to state the ASCVD risk of stopping (sources/lipid-aha-2026).
- Practical ladder: reduce dose → alternate-day dosing → switch to a different statin → add bempedoic acid or ezetimibe → PCSK9 mAb.
Nonstatin Agents
| Agent | LDL-C reduction | Route | Key evidence |
|---|---|---|---|
| Ezetimibe | 18% alone; +25% with statin | Oral daily | IMPROVE-IT |
| Evolocumab | 45–64% | SC every 2 weeks | FOURIER |
| Alirocumab | 45–64% | SC every 2–4 weeks | ODYSSEY OUTCOMES |
| Inclisiran | 48–52% | SC, then every 6 months | ORION-10/11; ORION-4 neutral by its own threshold |
| Bempedoic acid | 21–24% alone; +17–18% with statin | Oral daily | CLEAR Outcomes (13% MACE reduction) |
| Bile acid sequestrants | 10–27% | Oral | Limited outcome data; GI side effects |
| Obicetrapib (investigational) | ~30% add-on | Oral daily | BROADWAY; outcome trial ongoing |
The reduction figures are the ACC/AHA class summary (sources/lipid-aha-2026, rating: very high). Bempedoic acid is COR I B in ESC 2025 for statin-intolerant patients and COR IIa C as add-on to maximum tolerated statin ± ezetimibe, with hyperuricaemia/gout, raised liver enzymes and renal impairment as its characteristic adverse effects (sources/lipid-esc-2025). Obicetrapib is not approved and not guideline-recommended; see concepts/CETP-Inhibitors.
PCSK9-Directed Therapy — Summary Only
Three points belong on this page; the trials do not.
- Both monoclonal antibodies reduce MACE by ~15% on optimised statin therapy, with benefit consistent down to very low achieved LDL-C and no signal of harm at those levels (sources/pcsk9-inhibitors-nrc-2018, rating: very high).
- Inclisiran's outcome evidence is weaker. ORION-4 (n=15,000) reported HR 0.84 at P=0.01, which did not meet its own pre-specified P<0.005 threshold — directionally favourable but statistically neutral by the trial's own criterion, against FOURIER's P<0.001. The lower achieved LDL-C reduction (~50% vs ~60%) is the most likely explanation; the guideline ranking gap (COR 2b vs 2a) follows from it (sources/inclisiran-orion-nejm-2020, rating: high).
- Full trial data, subgroup analyses, genotype-specific dosing in HoFH and the anti-inflammatory mechanism controversy are on concepts/PCSK9-Inhibitors; the siRNA pharmacology is on entities/Inclisiran.
Secondary Prevention — Chronic Coronary Disease
- High-intensity statin, COR 1/A, aiming ≥50% LDL-C reduction. Monitor lipids at 4–12 weeks after initiation or dose change, then every 3–12 months (sources/CCS-AHA-2023, rating: very high).
- Very high risk is defined as ≥2 major ASCVD events, or 1 major event plus ≥2 high-risk conditions. Major events: recent ACS (≤12 months), prior MI, ischaemic stroke, symptomatic PAD. High-risk conditions: age ≥65, familial hypercholesterolaemia, prior CABG/PCI outside the major event, diabetes, hypertension, CKD (eGFR 15–59), current smoking, LDL ≥100 mg/dL on maximum statin plus ezetimibe, history of heart failure (sources/CCS-AHA-2023).
- Ezetimibe, COR 2a/B-R, for very high risk with LDL ≥70 mg/dL on maximum statin: IMPROVE-IT showed 7% relative risk reduction, with greater absolute benefit in those carrying ≥3 high-risk features (sources/CCS-AHA-2023).
- PCSK9 mAb, COR 2a/A, for very high risk with LDL ≥70 or non-HDL ≥100 mg/dL on maximum statin plus ezetimibe (sources/CCS-AHA-2023).
- Niacin, fenofibrate and dietary omega-3 supplements are COR 3: No Benefit on a statin background (AIM-HIGH, HPS2-THRIVE, ACCORD-LIPID, PROMINENT). Fenofibrate retains a role only for triglycerides ≥500 mg/dL to prevent pancreatitis. See concepts/Hypertriglyceridemia-Management.
- Icosapent ethyl, COR 2b/B-R, for LDL <100 plus triglycerides 150–499 mg/dL on a statin; REDUCE-IT showed 25% MACE reduction with incident AF more frequent (sources/CCS-AHA-2023).
Secondary Prevention — ACS
- ACS patients carry markedly higher event rates than stable chronic coronary disease, which is what justifies more aggressive LDL-C lowering immediately (sources/ACS-AHA-2025, rating: very high).
- High-intensity statin immediately post-ACS, Class I/A, independent of baseline LDL-C; do not de-escalate if tolerated.
- Nonstatin if LDL-C ≥70 mg/dL on maximal statin: Class I/A. Options are ezetimibe (IMPROVE-IT), alirocumab (ODYSSEY OUTCOMES), evolocumab (FOURIER), with inclisiran and bempedoic acid also listed.
- Nonstatin if LDL-C 55–69 mg/dL on maximal statin: Class IIa/B-R. Supported by secondary analyses of FOURIER and ODYSSEY showing monotonic benefit at lower achieved LDL-C, with no neurocognitive or muscle safety signal.
- Concurrent ezetimibe with the initial statin: Class IIb/B-R in ACC/AHA, upgraded to COR IIa B by ESC 2025 for treatment-naive patients at the index admission (sources/lipid-esc-2025).
- Lipid reassessment 4–8 weeks after initiating or adjusting therapy, Class I/C-LD. LDL-C falls modestly within 24 hours of symptom onset, so the admission lipid panel should be drawn as early as possible (sources/ACS-AHA-2025).
Special Populations
- CKD stage 3+: statin ± ezetimibe ± PCSK9 mAb for ASCVD (COR 1 for ASCVD with CKD ≥3). Statins are not beneficial in dialysis — two large RCTs were negative (sources/lipid-aha-2026, rating: very high).
- HIV, age 40–75 on stable ART: pitavastatin COR 1 on the basis of REPRIEVE (35% MACE reduction); pitavastatin is preferred because its minimal CYP3A4 metabolism limits interactions with antiretrovirals. ESC 2025 extends this to all people with HIV aged ≥40 in primary prevention, irrespective of estimated cardiovascular risk and LDL-C (COR I B) — a rare case where a risk calculator is explicitly bypassed (sources/lipid-esc-2025, rating: very high).
- Cancer and cardio-oncology: statins should be considered in patients at high or very high risk of chemotherapy-related cardiotoxicity to reduce anthracycline-induced dysfunction (ESC 2025, COR IIa B; STOP-CA, atorvastatin 40 mg, 22% vs 9% LVEF decline). Cancer survivors with life expectancy ≥2 years are treated as if they had no cancer history; statins continue in active cancer unless there is a drug interaction or life expectancy <1 year (sources/lipid-esc-2025).
- Pregnancy: the FDA removed statin use in pregnancy as a contraindication in 2024 and ACC/AHA 2026 reflects this, while ESC 2025 does not address it; statins should be avoided during lactation. For triglycerides ≥500 mg/dL, fibrates after the first trimester or high-dose omega-3 ethyl esters are reasonable (COR 2a) (sources/lipid-aha-2026).
Older Adults — STAREE
The first adequately powered randomized test of statin initiation for primary prevention at age ≥70, and the first large trial to use disability-free survival as a prespecified co-primary end point (sources/lipid-staree-nejm-2026, rating: very high).
- Design: 9,971 community-dwelling Australians ≥70 without cardiovascular disease, diabetes or dementia (mean age 74.7; 40.4% ≥75); atorvastatin 40 mg daily versus placebo; double-blind; median 5.9 years; no industry involvement; 99.9% vital-status ascertainment.
- Major cardiovascular events reduced: 10.9 versus 15.5 per 1000 person-years; HR 0.70 (95% CI 0.61–0.82; P<0.001) — about one event prevented per 217 patient-years.
- Disability-free survival not improved: 21.6 versus 23.0 per 1000 person-years; HR 0.94 (0.84–1.05; P=0.25). Dementia was identical (HR 1.03) and all-cause death was not reduced (HR 0.91, 0.79–1.04). Eighty per cent of deaths in the trial were non-cardiovascular.
- Cardiovascular death was exactly null: 74 events in each arm, HR 1.00 (0.72–1.37). The composite is carried entirely by nonfatal myocardial infarction (HR 0.58) and coronary revascularisation (HR 0.57); stroke was not significant.
- The authors consider their estimate conservative, because 13% of the placebo arm took open-label statins.
| Safety event | Atorvastatin | Placebo |
|---|---|---|
| Any adverse event | 63.0% | 58.7% |
| Serious adverse event | 2.7% | 2.7% |
| Hepatobiliary, any | 3.3% | 0.9% |
| Hepatobiliary, medically important | 1.4% | 0.3% |
| Diabetes and diabetes-related, any | 4.0% | 2.7% |
| Musculoskeletal, any | 32.0% | 29.4% |
| Musculoskeletal, serious | 0.2% | 0.2% |
Serious adverse events were identical, and the excess sits in non-serious categories — but the four-fold hepatobiliary signal and the diabetes excess are the best randomized safety estimates available for this age group. Adherence was the practical limit: discontinuation for "participant unwilling" (15.6% vs 16.2%) exceeded discontinuation for adverse events, against real-world five-year statin adherence of only 25–50%.
Monitoring After Initiation or Escalation
- Lipid profile 4–12 weeks after starting or changing therapy, then every 3–12 months (COR 1) (sources/CCS-AHA-2023).
- Routine CK measurement: not recommended (COR 3), unless severe symptoms.
- Routine hepatic transaminase monitoring: not recommended (COR 3); check only if there are symptoms of hepatotoxicity (sources/lipid-aha-2026).
- After a PCSK9 mAb or inclisiran is started, the same timing applies; the parent page covers ApoB as the intensification marker once LDL-C and non-HDL-C goals are met.
Contradictions / Open Questions
- Bempedoic acid and inclisiran are ranked by a guideline written before their outcome data existed. CCS/AHA 2023 places both at COR 2b and states explicitly that no MACE outcome data existed at publication; CLEAR Outcomes subsequently reported a 13% MACE reduction with bempedoic acid. ESC 2025 has already moved bempedoic acid to COR I B for statin intolerance. The two societies are now describing different drugs with the same name, and the ACC/AHA ranking should be treated as superseded rather than current (sources/CCS-AHA-2023, sources/lipid-esc-2025).
- Inclisiran lowers LDL-C nearly as well as a PCSK9 mAb but has not shown the same outcome benefit. ORION-4 missed its own pre-specified threshold (HR 0.84, P=0.01 against P<0.005) while FOURIER and ODYSSEY OUTCOMES were unequivocal. Whether this reflects the smaller absolute LDL-C reduction, a shorter effective exposure, or a population difference is unresolved. The practical consequence is that inclisiran is most defensible where adherence, not potency, is the limiting problem — twice-yearly administration by a clinician (sources/inclisiran-orion-nejm-2020).
- No trial has compared "reduce the statin dose and add a drug" against "switch statin" in statin-associated muscle symptoms. Both ACC/AHA COR 1 rules in established ASCVD describe the add-on strategy, and bempedoic acid's CLEAR Outcomes population was largely statin-intolerant — so the add-on route has outcome support. Whether a patient who tolerates no statin at all is better served by bempedoic acid or by a PCSK9 mAb is a cost-and-access question the guidelines do not settle (sources/lipid-aha-2026).
- The early-combination question at ACS is answered differently by two guidelines published a year apart. ESC 2025 gives statin plus ezetimibe at the index admission COR IIa B; ACC/AHA 2025 gives concurrent ezetimibe Class IIb/B-R. Neither is based on a trial of the timing strategy itself — IMPROVE-IT added ezetimibe at a median of 5 days post-ACS, which supports early use but does not compare early against delayed (sources/lipid-esc-2025, sources/ACS-AHA-2025).
- ACC/AHA 2026's secondary prevention wording has an unresolved ambiguity. For patients who are not very high risk, the recommendation sets a goal of LDL-C <70 mg/dL and then adds "add ezetimibe/PCSK9 mAb/bempedoic acid to reach <55 mg/dL (COR 2a)". Whether <55 is intended as a goal for all secondary prevention once escalation is under way, or only as a permissive floor for those who tolerate further intensification, is not stated. Clinical practice has read it the second way; the text supports the first (sources/lipid-aha-2026).
- STAREE establishes nonfatal benefit at ≥70 but not the outcome patients are usually asking about. Major cardiovascular events fall by 30%, yet disability-free survival, dementia and all-cause death are unchanged and cardiovascular death is numerically identical. The trial was double-blind, so the revascularisation endpoint cannot be dismissed as allocation-aware behaviour — but it remains a procedure-sensitive endpoint. What to tell a 74-year-old weighing roughly one event prevented per 217 patient-years against a four-fold hepatobiliary adverse-event excess is a shared-decision question the trial does not answer (sources/lipid-staree-nejm-2026).
- Age boundary mismatch: ACC/AHA guidance addresses "age >75" while STAREE enrolled from ≥70, and none of the trial's endpoints map onto the existing individualised "can be considered" position. The ≥70–74 group, which generated a large share of the trial's events, has no guideline position of its own (sources/lipid-aha-2026, sources/lipid-staree-nejm-2026).
Connections
- Part of concepts/Dyslipidemia — the parent overview: risk assessment, thresholds, treatment goals, ApoB and non-HDL-C.
- Related to concepts/PCSK9-Inhibitors — full FOURIER/ODYSSEY data, ORION trials, HoFH dosing, safety profile.
- Related to concepts/CETP-Inhibitors — obicetrapib as an oral add-on below ezetimibe and above injectables in potency.
- Related to concepts/Hypertriglyceridemia-Management — when a fibrate or icosapent ethyl is added rather than further LDL-C lowering.
- Related to concepts/ASCVD-Risk-Assessment — PREVENT and SCORE2/SCORE2-OP determine who enters this pathway at all.
- Related to concepts/Familial-Hypercholesterolemia — the population where the escalation ladder is climbed fastest.
- Related to concepts/Lipid-Gene-Therapy — single-infusion base editing as the eventual alternative to lifelong dosing.
- Related to concepts/Heart-Healthy-Dietary-Patterns — dietary fat quality as the non-pharmacological first step.